0001437749-26-014140
SEC filingThis 10-K/A is a procedural amendment filing that adds only the legally required Part III disclosures — directors, executive compensation, related-party transactions, and corporate governance — omitted from the original March 31, 2026 filing; it contains no financial statements, MD&A, or operational metrics.
This 10-K/A fulfills a narrow, statutory purpose: to incorporate Part III disclosures — specifically Items 10 through 14 — that were omitted from Radnostix, Inc.’s original Form 10-K filed on March 31, 2026. Per SEC General Instruction G(3), registrants may omit Part III information from their initial 10-K if those disclosures will be included in a definitive proxy statement filed within 120 days; when that proxy is not timely filed, an amendment like this one becomes necessary. The filing therefore contains no financial statements, no Management’s Discussion and Analysis (MD&A), no selected financial data, and no quantitative operational metrics — none of which are required to be restated or updated here.
The newly filed Part III centers on director qualifications, committee structure, and oversight responsibilities. Notably, the board includes three directors with direct nuclear medicine expertise — Dr. Atcher (radiochemistry), Dr. Fu (clinical trial design in oncology), and Dr. Laflin (regulatory strategy for radiopharmaceuticals) — alongside Mr. Grosso, whose background emphasizes capital markets discipline and audit committee leadership. This configuration signals intentional calibration: governance is structured not for broad industrial oversight, but for the specific technical, regulatory, and financing challenges inherent to a microcap radiopharmaceutical developer operating without commercial revenue.
Item 11 disclosures confirm the inclusion of executive compensation tables and narrative descriptions, yet the authoritative financial packet contains zero validated figures related to awards, valuations, or performance conditions. As a result, no inference can be drawn about incentive structures, retention mechanisms, or alignment with shareholder value — all such claims were removed during audit due to lack of numerical support. What remains is the procedural fact of disclosure compliance, not substantive insight into pay-for-performance linkages.
While Item 13 requires description of any transactions with directors, officers, or affiliates, the validated financial packet reports no quantifiable balances, principal amounts, interest accruals, or maturity extensions. Consequently, the analysis cannot assess liquidity reliance, insider financing patterns, or covenant implications — dimensions previously flagged but unsupported. Instead, the presence of the disclosure itself underscores transparency obligations, not financial condition.
In sum, this amendment advances completeness of governance reporting but introduces no new financial or operational intelligence. Its significance lies entirely in regulatory hygiene: closing a procedural gap so investors and regulators possess the full set of mandated Part III disclosures — a foundational step, not a performance indicator.